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Abstract
Background: Obesity is an increasing disease worldwide. Bariatric surgery is the only effective therapy to induce
sufficient long-term weight loss for morbidly obese patients. Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) is the
gold standard surgical technique. Laparoscopic Sleeve Gastrectomy (LSG) is a new promising bariatric procedure
which has the advantage of maintaining an intact gastrointestinal tract. The aim of this study is to evaluate the
efficiency of both techniques. Our hypothesis is that LSG has a similar percentage excess BMI loss (%EBMIL) after
5 years compared to LRYGB.
Methods/Design: The Sleeve Bypass Trial is a randomized multicentre clinical trial: patients eligible for bariatric
surgery are randomized to either LSG or LRYGB. Patients with a body mass index (BMI) ≥ 40 kg/m2 or BMI 35 kg/m2
with obesity related comorbidity (T2 DM, sleep apnoea, hypertension) are eligible for randomization. At randomization
patients are stratified for centre, sex, T2 DM and BMI≥ 50 kg/m2. A total number of 620 patients will be enrolled and
equally (1:1) randomized to both treatment arms. Only surgeons experienced in both operation techniques will
participate in the Sleeve Bypass trial. The primary endpoint is the 5-year weight loss (%EBMIL) of LSG and LRYGB.
Secondary endpoints are resolution of obesity related comorbidity, complications, revision bariatric surgery and quality
of life (QOL) defined in various questionnaires.
Discussion: Long-term %EBMIL between the two treatment strategies used to be in favour of LRYGB, but more recent
results throughout the world show similar %EBMIL in both techniques. If weight loss is comparable, obesity-related
comorbidity and QOL after bariatric procedures should be taken into account when deciding on which surgical
technique is to be preferred for certain subgroups in the future.
Trial registration: Dutch Trial Register: NTR 4741.
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Background
Obesity is a global problem. It induces health risks, di-
minishes quality of life, psychosocial problems and in-
creases public costs. When patients become morbidly
obese, health risks increase rapidly [1]. Morbid obesity is
defined as having a body mass index (BMI) ≥ 40 or BMI
35 kg/m2 combined with at least one comorbid condi-
tion, such as type 2 diabetes (T2 DM), hypertension,
dyslipidaemia, or sleep apnoea.
Bariatric surgery is considered the best treatment to
realize long-term sufficient weight loss in morbidly
obese patients [2–4]. Besides weight loss, it also has pro-
found effects on obesity-related comorbidities, such as
T2DM, hypertension and sleep apnoea [5, 6].
Laparoscopic Roux-en-Y gastric bypass (LRYGB) is con-
sidered the best surgical option for morbid obesity and as
a result is still one of the most frequently performed bar-
iatric procedure worldwide [7, 8]. There are advantages of
LRYGB being fully reversible, well documented in terms
of early morbidity and long term results known for more
than 50 years and often regarded as the gold standard in
bariatric and metabolic surgery. Laparoscopic sleeve gas-
trectomy (LSG) is a relatively new procedure which
started as a first stage procedure before a duodenal switch
(DS) in super obese patients to reduce treatment related
mortality. As weight loss results following LSG were ex-
cellent, necessitating a second stage procedure in only a
quarter of the patients, LSG is currently used as a single
stage procedure in morbidly obese patients. LSG is be-
coming more popular and is performed in 28 % of bariat-
ric procedures worldwide in 2011 [8]. LSG has some
potential advantages; it is a faster and safe procedure
where the duodenum is still accessible for endoscopy,
there is less dumping due to the pylorus and second stage
procedures (LRYGB or BPD-duodenal switch) are stand-
ard procedures. The most profound possible disadvantage
is that LSG is irreversible. Quality of life (QOL) appears to
be similar or even better after LSG compared to LRYGB
due to the mentioned advantages [9, 10].
So far results of RCTs with small number of patients
and short-term outcome have been published only. In
these studies the percentage excess BMI loss (%EBMIL)
appeared to be equal for both techniques [9, 11–16].
However, concerns remain that the sleeve will lose its ef-
fect in time, resulting in a decline of weight loss and re-
appearance of obesity-related comorbidity [17].
Methods/Design
Study objective
The primary aim of this multicentre study is to compare
LSG with standard LRYGB in terms of percentage excess
BMI loss (%EBMIL) as well as in secondary outcomes
(e.g. QOL, resolution of obesity-related-comorbidity, com-
plications and revision bariatric surgery due to insufficient
weight loss or GERD). In order to determine the area of
indication for the LSG in the field of bariatric surgery pa-
tients in this study are also stratified at randomisation for
sex, T2 DM and a BMI below or above 50 kg/m2.
Study design
The sleeve versus bypass trial is a randomized multi-
centre trial, in which two bariatric medical centres are
participating. The study started on November 24th 2012
and the duration of the inclusion will be approximately
3 years. The study compares the %EBMIL of LSG and
LRYGB after five years (primary endpoint). Patients with
morbid obesity with a BMI ≥ 40 kg/m2 or BMI 35 kg/m2
with obesity related comorbidity (T2 DM, sleep apnoea,
hypertension) are eligible for randomization. In total 620
morbidly obese patients will be included in the study.
Approval of the medical ethical committee of both par-
ticipating centres, “Toetsingcommissie Wetenschappelijk
Onderzoek Rotterdam” and “Medisch Ethische Toetsing-
commissie Catharina Ziekenhuis Eindhoven” was ob-
tained. After approval the trial is accepted and registered
in the Dutch trial register. The complete route of patient
inclusion and randomisation is depicted in Fig. 1.
Patients will be randomized, using a randomization
website to one of the following bariatric procedures:
1. Laparoscopic sleeve gastrectomy (LSG)
The LSG is performed by a full mobilisation of the
greater curvature and the posterior stomach,
followed by stapling calibrated over a 34 french
boogie, starting 2–3 cm’s from the pylorus. The used
technique is described in 2012 and proven to be
effective and safe [18].
2. Laparoscopic Roux-and-Y gastric bypass (LRYGB)
The LRYGB is performed with the antecolic linear
technique. A small 4 cm long pouch is calibrated
over a 34 french boogie and 3 cm linear
gastroenterostomy is realized. The measured
biliopancreatic limb is 60 cm and the alimentary
limb is 150 cm. The omentum can be divided at the
surgeons’ discretion. Both mesenteric defects are
closed with clips [19].
Patient selection
All morbidly obese patients who have been approved for
bariatric surgery by the preoperative multidisciplinary
team can be included in the sleeve versus bypass trial.
Informed consent is mandatory. The criteria for bariatric
surgery are age 18–60 years, BMI > 40 kg/m2, or BMI >
35 kg/m2 with obesity-related comorbidity (such as T2
DM, hypertension, hypercholesterolemia, severe arthro-
sis and OSAS) for more than 3 years, conservative ther-
apy (preferably under the guidance of a physician or
self-help group) that has failed or showed only transient
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results, completion of psychological screening, excluding
patients with psychiatric and psychological disorders,
written informed consent and willingness to conclude
the lifelong follow up program after surgery.
Exclusion criteria for this study are: a history of diag-
nosed symptomatic gastro oesophageal reflux disease
(GERD) [20], or a diagnosed hiatal hernia with symp-
toms. There is no routine gastroscopy prior to surgery
in asymptomatic patients. Other exclusion criteria are
severe sweet eating [21], prior bariatric surgery, prior
major abdominal surgery (such as colonic resection, ab-
dominal sepsis, aortic surgery, which might jeopardise
the technical feasibility of LSG or LRYGB) and the in-
ability of reading or understanding the questionnaires.
Hypothesis
Our hypothesis is that LSG has a comparable %EBMIL
after 5 years when compared to LRYGB [22–26]. Even
if LSG is marginally less effective compared to LRYGB
in terms of long term %EBMIL, QOL might be better
from a dietary and long term complications point of
view [27-29].
Study questions
Primary Question: Does LSG result in a similar long
term %EBMIL after a follow up period of 5 years when
compared to the LRYGB?
Secondary Question: Is the QOL better after a LSG
compared with the LRYGB?
Fig. 1 CONSORT flowchart
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Other secondary endpoints: improvement in obesity
induced co-morbidity, complication rate, readmission
and reoperation rate, revision surgery rate, operating
time and duration of hospital stay and the predictive
value of sweet eating habit inventoried by the Dutch
Sweet Eating Questionnaire (DSEQ) [21].
Surgical intervention
All patients are treated in a fast-track protocol [30] and
discharged 1 day after surgery. Antithrombotic prophy-
laxes (Fragmin® 5000 u/day) and a fluid diet is continued
for 2 weeks postoperatively. All patients are prescribed
proton pump inhibitors for 6 weeks after surgery. Follow
up of patients will be performed in an outpatient clinical
setting [Table 1].
The patient is called by the obesity nurse in the first
week. Outpatient clinic visits are scheduled at 6 weeks,
3, 6 and 12 months and then once annually. The stand-
ard follow up [Table 1] is combined with extra visits in
case of complaints or possible complications with a 24 h
access to the bariatric surgery department. The compli-
cations are scored at every consultation using the “Clavien-
Dindo classification” to score the severity [31].
All participating surgeons are experienced bariatric
surgeons that have performed at least 150 LSG and 150
LRYGB and work in bariatric centres of excellence that
perform over 500 cases per year.
Laparoscopic sleeve gastrectomy
Two different known approaches have been described in
the literature [32, 33]: the stapling first technique or the
full mobilisation of the greater gastric curvature first
technique. As a tight gastric sleeve, which is important
for an optimal weight loss result, seems to be realised
best by the gastric mobilisation first technique [18] this
is the only LSG technique used for this study.
1. Starting
After achieving pneumoperitoneum, with a Veress
needle in the left upper quadrant, five trocars are
placed according to the surgeons preference.
2. Mobilization
The greater curvature is dissected downward to 2–
3 cm proximal to the pylorus. Next the greater
curve is further mobilized up to the angle of His,
visualizing the complete left diaphragm crus. While
mobilizing the greater curve all gastro-pancreatic
adhesions at the dorsal smaller gastric curve are also
released in upward direction towards the angle of
His. This step is important in order to be able to
realize a small gastric sleeve without redundant
fundus at the dorsal gastric wall.
3. Stapling
A linear 60 mm endoscopic stapler is introduced
through the right trocar and fired at the antrum,
leaving just enough space for a gastric boogie to pass.
Next an orally introduced gastric tube is inserted up
to the pylorus. This gastric tube is 34 French (Fr) in
diameter as it is important to create a small gastric
sleeve. A tight sleeve is realised by firing another 4–5
60 mm long linear staple lines using the same trocar
site. The stapler is placed tight to the tube while
stretching the greater curve. Each time after placing
the stapler the gastric tube is moved by the
anaesthesiologist under laparoscopic vision in order to
ensure that the stapler has not been placed on the
tube itself. The last stapler is fired lateral to Belsy’s fat
leaving the oesophagus unharmed.
4. Finishing
Next, the left trocar site is dilated and the resected
stomach is removed. Subsequently, this trocar site is
closed at fascia level. The gastric tube is removed by
the anaesthesiologist under laparoscopic vision. Staple
line bleeding is controlled by clips and when necessary
with sutures. Only in case of bleeding, stapling
problems, or other difficulty, a drain is placed along
the sleeve gastrectomy. Over-sewing of the staple line
is not routinely performed. Next, the trocars are
removed under sight and the skin is closed.
Laparoscopic Roux-en-Y gastric bypass
1. Starting
After achieving pneumoperitoneum, with a Veress
needle in the left upper quadrant, five trocars are
placed according to the surgeons preference.
2. Gastric pouch creation
At the gastro oesophageal junction Belsy’s fat is
released from the left diaphragm crus.






1 Week Obesity nurse Obesity nurse
6 Weeks Surgeon Surgeon Obesity nurse
3 Months Endocrinologistb Endocrinologistb
6 Months Endocrinologistb Endocrinologistb Obesity nurse
9 Months Endocrinologistb Endocrinologistb
12 Months Surgeon Surgeon Obesity nurse
Annualy Endocrinologistb Endocrinologistb Obesity nurse
aChanges in health status over time are measured using generic and disease
specific quality of life questionnaires (Euro-Qol 5D, Short Form 36 (SF-36) and
the Gastro-Intestinal Quality of Life Index (Qiqli)) on admission and after 6,
12 months and then annually. Obesity related quality of life questionnaires
(the Moorehead-Ardelt II) and the Bariatric Analysis and Reporting Outcome
System (BAROS) score are measured at the same time-intervals. Sweet eating
will be established with the Dutch Sweet Eating Questionnaire (DSEQ)
bEvery visit to the endocrinologist is combined with extensive
laboratory testing
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Next, at the lesser curve, approximately 4 cm below
the angle of His, the minor omentum is released
from the lesser gastric curve until an opening is
created in the omental burse. A 60 mm linear
endostapler is used to transect the lesser curve
horizontally. Then, the gastro-pancreatic adhesions
are released and 2 more 60 mm linear endostaplers
are fired in vertical direction along a calibrating 34
Fr gastric tube that has been inserted transorally.
Thus a small and calibrated gastric pouch is created.
3. Omental split
In order to make the pathway of the small bowel
towards the gastric pouch shorter the greater
omentum can be split vertically.
4. Creation of gastro-enterostomy
The small bowel is brought upward towards the
gastric pouch at a length of 60 cm from the point of
Treitz. At this point a small defect is created in the
small bowel as well as in the left caudal corner of
the pouch. A linear endostapler is fired at 3 cm’s
length. The anastomosis is closed by laparoscopic
suturing. The gastro-enterostomy is tested by
methylene blue injected through a gastric tube. If
the test indicates leakage, this point is sutured and
the methylene blue test is repeated.
5. Creation of entero-enterostomy
A linear stapler is fired and the remaining defect is
sutured creating an entero-enterostomy between the
small bowel proximal to the gastro-enterostomy
and the small bowel 150 cm distally from the
gastro-enterostomy.
6. Finishing
Petersen’s space and the mesenteric defect at the
entero-enterostomy are closed by a laparoscopic
clipping device [19]. Staple line bleeding is controlled
by clips and when necessary with sutures. The trocars
are removed under sight and the skin is closed.
Escape surgery
If it is technically impossible to perform an LRYGB dur-
ing surgery, it is allowed to perform a LSG. Moreover, if
there are technical problems during LSG e.g. creating an
occlusion of the sleeve or stapling of the oral tube, con-
version to LRYGB surgery is allowed. The statistical ana-
lysis will be according to the intention-to-treat principle
and a per protocol analysis.
Outcome measures
Primary endpoint
Sustainable weight loss. The amount of weight loss is
expressed as percentage excess BMI loss (%EBMIL), and
calculated with the formula %EBMIL = (pre-operative
BMI – current BMI)/(pre-operative BMI – ideal BMI) ×
100 %. For this formula a BMI of 25 kg/m2 was taken as
the upper limit of normal, i.e. the ideal BMI.
Secondary endpoints
To evaluate operating time, duration of hospital stay,
intra-operative and post-operative in-hospital mortality
and morbidity following LSG or LRYGB. Morbidity is
defined as re-operations, re-interventions, re-admissions
and serious adverse events. Morbidity is also defined as
major (anastomotic leakage, major peroperative blood loss
due to splenic or vascular haemorrhage, pulmonary em-
bolism, intra-abdominal abscess and intra-abdominal
hematoma) or minor (wound infection, urinary tract in-
fection and anastomotic stenosis). Moreover, the rate of
extra outpatient and emergency room visits because of
complaints following LSG or LRYGB are evaluated.
Preoperatively all patients are assessed by an multidis-
ciplinary team consisting of at least surgeons, endocrinol-
ogists, physiotherapists, nutritionists, and psychiatrists.
The endocrinologist defines the comorbidities using
the definitions from common international guidelines
[34] for hypertension, dyslipidaemia, T2 DM, obstructive
sleep apnoea syndrome (OSAS) and joint pain. The sur-
geon defines gastro oesophageal reflux disease (GERD)
as need for proton pump inhibitor (PPI) agents and/or
esophagitis diagnosed on endoscopy. To evaluate the
biochemical changes following LRYGB or LSG in the
first year extensive laboratory tests are obtained every
3 months. This is continued in the yearly visits which
are common practice in our clinics. If patients fail to at-
tend follow up they will be contacted by telephone to
motivate them to return to the follow up or the patient’s
general practitioner will be contacted in order to
minimize the lost-to-follow up. To evaluate remission or
improvements of the various comorbidities the use of
medication is documented and adjusted where necessary
during each visit. The remission of a co-morbidity was
defined when patients no longer needed a drug therapy
and had normal blood pressure. In T2 DM remission
was defined as a normal fasting glucose, without medica-
tion and a glycosylated haemoglobin (HbA1c) of <6 %.
Improvement was defined as changing from insulin to
oral antidiabetic drugs or lowering the dose or number
of drugs needed.
To evaluate QOL multiple questionnaires are used.
QOL was objectified by the asthma control question-
naire (ACQ), the reflux disease questionnaire (Gerd-Q),
the Bariatric Analysis and Reporting Outcome System
(BAROS) score, the Gastro-intestinal Quality of life
Index (GIQLI), EuroQol-5D (EQ-5D), Short-form 36
(SF-36) before and following LSG or LRYGB.
To evaluate the predictive value of the Sweet eating in-
ventoried by the Dutch Sweet Eating Questionnaire
(DSEQ) [17].
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To evaluate the need for revision surgery (need to per-
form an additional bariatric procedure after the per-
formed surgery) as a result of insufficient weight loss or
medical complaints within 5 years following the primary
bariatric procedure (LSG or LRYGB). Insufficient weight
loss is defined with the Reinhold criteria (modified by
Christou and Biron).
All data will be collected in a digital patient form in
order to ensure completeness of data.
Data and safety monitoring committee
To ensure patient safety and study integrity, an inde-
pendent data and safety monitoring committee is
established, which will evaluate the progress of the
trial and will examine safety parameters at regular in-
tervals of 100 included patients. All involved physi-
cians need to report any potential adverse events
encountered in this study and these potential adverse
events will be discussed with the monitor committee.
The monitoring committee can request a full report in
order to discuss a specific adverse event and this re-
port will be sent to the central ethics committee and
all involved physicians.
All deceased patients will be evaluated by the safety
committee for cause of death and possible trial related
serious adverse events. All deaths will be reported to the
central ethics committee and the local ethics board. The
DSMB consists of an epidemiologist/statistician, an inde-
pendent surgeon and an independent endocrinologist.
Power calculation
The data of the randomized subjects are analysed ac-
cording to the intention to treat principle. Follow up will
be completed until 5 years after the operation.
For the sample size determination the used hypothesis
for the study are:
H0: mean %EBMIL (LSG) =mean %EBMIL (LRYGB)
H1: mean %EBMIL (LSG) ≠mean %EBMIL (LRYGB)
To be able to reject the null hypothesis that mean
%EBMIL after LSG treatment equals mean %EBMIL
after LRYGB, at least 2×294 analysable patients have to
be included (mean (SD) %EBMIL is 68.59 (25.88) after
LSG and 62.60 (25.88) after LRYGB; type I error: 0.05
(two sided), type II error = 0.20 (power = 80 %), ran-
domization ratio 1:1). Considering a dropout rate of
5 %, the sample size is estimated to be 2×294/.95 =
2×310 = 620.
The %EBMIL data of LSG and LRYGB are obtained
from the meta analysis of Garb et al. [35]. The standard
deviation of LRGYB is assumed to be equal to the stand-
ard deviation of LSG.
Discussion
Laparoscopic sleeve gastrectomy (LSG) is a relative new
procedure which was first described by Marceau and
Hess in the 1990s as a part of the BPD duodenal switch
and LSG is later popularized by Regan and Gagner as a
first stage procedure prior to a duodenal switch (DS) in
super obese patients to reduce treatment related mortal-
ity [32]. The weight loss results following LSG were ex-
cellent, resulting in a second stage procedure in only a
quarter of the patients. Therefore, LSG is currently used
as a single stage procedure in morbidly obese patients
resulting in a percentage excess BMI loss (%EBMIL) ran-
ging between 50 % and 83 % and having a favourable im-
pact on comorbidities [18–22]. In comparison with
LRYGB, LSG is technically more simple and faster to
perform. However, currently long term results of LSG
are limited compared to LRYGB. Another benefit of
LSG is the relatively normal dietary options for the pa-
tients, potentially improving QOL in comparison with
LRYGB. LRYGB associated dumping syndrome, caused
by large particles and carbohydrates directly entering the
small intestine, has been reported [23, 24]. Moreover,
patients treated by LSG have less nutritional deficits
compared to LRYGB [25]. Another benefit of LSG is
that, as the normal gastrointestinal tract is preserved,
diagnostic and therapeutic interventions such as gastros-
copy and ERCP are still possible. Especially the inability
to perform an ERCP can be a problem after LRYGB as
many morbidly obese patients suffer from bile stone re-
lated problems following bariatric surgery as a result of
weight loss and concurrent cholecystectomy has been
abandoned since this can increase perioperative risks and
complications. Furthermore, LSG can easily be converted
to LRYGB, BPD-DS or an omega loop bypass depending
on the patient characteristics and the preferences of the
surgeon in case of insufficient weight reduction. More-
over LSG results in a better QOL than LRYGB [9].
Currently, only few randomized controlled trials have
compared LSG and LRYGB [11, 19]. However, these
studies described small study groups and did not report
long-term results. Although their conclusions lack hard
evidence to determine in which patients these two differ-
ent techniques should be performed, these studies seem
to show a small short term beneficial result for LSG.
This study will contribute to the evidence of the bene-
fits of LSG versus the standard LRYGB.
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